Abstract:A single PNA test in its present form is as sensitive an indicator of colorectal neoplasia as Hemolex completed over three days, but lacks specificity. The 160 kD cancer-associated antigen we have identified is under further characterization for development of a more specific PNA test.
“…As a result, age-related differences in survival disappeared, indicating that probably colorectal cancer itself is not the main cause of age-related differences in survival. This is in line with earlier studies that found no age-related differences in cancer-specific survival 5–7. However, this remains intriguing, since many papers indicate that differences in survival between the young and the elderly can be attributed to undertreatment in the elderly 1,9.…”
Section: Discussionsupporting
confidence: 91%
“…Notwithstanding all these differences, several studies found similar disease-specific survival for elderly and young colorectal cancer patients 5–7. This would indicate that the excess mortality in elderly colorectal cancer patients is due to competing causes of death.…”
BackgroundElderly colorectal cancer patients have worse prognosis than younger patients. Age-related survival differences may be cancer or treatment related, but also due to death from other causes. This study aims to compare population-based survival data for young (<65 years), aged (65–74 years), and elderly (≥75 years) colorectal cancer patients.MethodsAll patients operated for stage I–III colorectal cancer between 1991 and 2005 in the western region of The Netherlands were included. Crude survival, relative survival, and conditional relative survival curves, under the condition of surviving 1 year, were made for colon and rectal cancer patients separately. Furthermore, 30-day, 1-year, and 1-year excess mortality data were compared.ResultsA total of 9,397 stage I–III colorectal cancer patients were included in this study. Crude survival curves showed clear survival differences between the age groups. These age-related differences were less prominent in relative survival and disappeared in conditional relative survival (CRS). Only in stage III disease did elderly patients have worse CRS than young patients. Furthermore, significant age-related differences in 30-day and 1-year excess mortality were found. Thirty-day mortality vastly underestimated 1-year mortality for all age groups.ConclusionsElderly colorectal cancer patients who survive the first year have the same cancer-related survival as younger patients. Therefore, decreased survival in the elderly is mainly due to differences in early mortality. Treatment of elderly colorectal cancer patients should focus on perioperative care and the first postoperative year.
“…As a result, age-related differences in survival disappeared, indicating that probably colorectal cancer itself is not the main cause of age-related differences in survival. This is in line with earlier studies that found no age-related differences in cancer-specific survival 5–7. However, this remains intriguing, since many papers indicate that differences in survival between the young and the elderly can be attributed to undertreatment in the elderly 1,9.…”
Section: Discussionsupporting
confidence: 91%
“…Notwithstanding all these differences, several studies found similar disease-specific survival for elderly and young colorectal cancer patients 5–7. This would indicate that the excess mortality in elderly colorectal cancer patients is due to competing causes of death.…”
BackgroundElderly colorectal cancer patients have worse prognosis than younger patients. Age-related survival differences may be cancer or treatment related, but also due to death from other causes. This study aims to compare population-based survival data for young (<65 years), aged (65–74 years), and elderly (≥75 years) colorectal cancer patients.MethodsAll patients operated for stage I–III colorectal cancer between 1991 and 2005 in the western region of The Netherlands were included. Crude survival, relative survival, and conditional relative survival curves, under the condition of surviving 1 year, were made for colon and rectal cancer patients separately. Furthermore, 30-day, 1-year, and 1-year excess mortality data were compared.ResultsA total of 9,397 stage I–III colorectal cancer patients were included in this study. Crude survival curves showed clear survival differences between the age groups. These age-related differences were less prominent in relative survival and disappeared in conditional relative survival (CRS). Only in stage III disease did elderly patients have worse CRS than young patients. Furthermore, significant age-related differences in 30-day and 1-year excess mortality were found. Thirty-day mortality vastly underestimated 1-year mortality for all age groups.ConclusionsElderly colorectal cancer patients who survive the first year have the same cancer-related survival as younger patients. Therefore, decreased survival in the elderly is mainly due to differences in early mortality. Treatment of elderly colorectal cancer patients should focus on perioperative care and the first postoperative year.
OBJECTIVES:Despite moderate to high detection rates of fecal immunochemical tests (FITs) of colorectal cancer (CRC), detection of adenomas remains limited. Further stool tests exist, which are not used in routine practice, such as DNA or RNA markers and protein markers. We aimed at systematically investigating and summarizing evidence for diagnostic performance of combinations of FIT with other stool tests compared with FIT alone in early detection of CRC and its precursors.METHODS:We systematically reviewed studies that evaluated FITs in combination with other stool tests and compared measures of diagnostic accuracy with and without additional stool tests. PubMed and Web of Science were searched from inception to May 2015. Reference lists of eligible studies were also screened. Two reviewers extracted data independently.RESULTS:Some of the reports on DNA, RNA, or tissue tests, including tests based on DNA mutations, methylation, and integrity in selected genes as well as microRNA expression, showed some improvements of diagnostic test accuracy. In contrast, so far assessed stool protein markers did generally not lead to substantial improvements in performance of FIT when added to the latter. Many marker combinations were reported only in one study each, and few studies were conducted in a true screening setting.CONCLUSIONS:Several stool markers show potential to improve performance of FITs. However, the results require confirmation in further studies, which should also evaluate the costs and cost-effectiveness of combined screening strategies.
“…Notwithstanding all these differences, several studies found similar disease-specific survival for elderly and young colorectal cancer patients [13,14]. This would indicate that the increase of mortality in elderly colorectal cancer patients is due to competing causes of patients: the age ≥ 85 y (p=0.005), the ASA III-IV score (p=0.002), the history of cardiac disease (p=0.047), the emergency admittance (p<10 -3 ), the bowel obstruction (p<10…”
Patient characteristics in both groups were compared using Chi-square with Fisher's exact test for qualitative variables. The normality of data was assessed by the the Shapiro-Wilk test and the Kolmogorov-Smirnov test. The Z Kolmogorov-Smirnov statistical
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.